Thrombosis Drugs Market (Drug Class - Factor Xa Inhibitor, Low Molecular Weight Heparin, P2Y12 Platelet Inhibitor; Indication - Pulmonary Embolism, Atrial Fibrillation, Deep Vein Thrombosis; Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2022-2030

According to Nova one advisor, the global Thrombosis Drugs market size is expected to hit around USD 51.7 billion by 2030 from valued at USD 25.9 billion in 2021 and growing at a CAGR of 11.2% from 2022 to 2030.

The Notable growth would be charted by global thrombosis drugs market, creating a string of advantageous opportunities and driving the market valuation to a higher worth. Multiple factors of growth are helping the global thrombosis drugs market stay on an upward and steep growth curve over the stated period. Some of these include poor lifestyle choices gaining foothold among consumers, increasing burden of cardiovascular diseases, and growing government efforts towards improvement in healthcare outcomes.

A detailed overview of trends and drivers that are contributing significantly to growth in the global thrombosis drugs market can be found below:

  •  Number of people in the geriatric age group is increasing and it is increasing at a rapid pace. As per research undertaken recently, there would be an increase from approximately 970million in 2017 to 2 billion in 2050 in the number of people aged 60 and above. This phenomenon is going to be quite pronounced in regions of Europe and North America where one in every four people will be aged 65 and above by this year. One in every six people will be the ratio of people in this age group across the world. This demographic is a major consumer of thrombosis drugs and is therefore set to propel notable growth in the market.
  • Research and development in the market is witnessing increase in activity and intensity – a result of growing number of cases of cardiovascular diseases. Poor diet and habits such as excessive drinking and smoking is leading to increase in incidence of these diseases across the globe. This is contributing massively to growth that is anticipated in the global thrombosis drugs market. Additionally, obesity or being over-weight is also increasing the risk of CVD, driving demand for thrombosis drugs by a notable factor over the forecast period,

Report Scope of the Thrombosis Drugs Market

Report Coverage

Details

Market Size

USD 51.7 Billion by 2030

Growth Rate

CAGR of 11.2% from 2022 to 2030

Largest Market

North America

Fastest Growing Market

Asia Pacific

Base Year

2021

Forecast Period

2022 to 2030

Segments Covered

 and Region,

Companies Mentioned

 Pfizer, Aspen Pharmacare Holdings Limited, Bayer AG, AstraZeneca plc, Sanofi, Johnson & Johnson, Bristol-Myers Squibb Company, Baxter International Inc., Boehringer Ingelheim GmbH, and GlaxoSmithKline plc.

              

Thrombosis Drug Market: Growth Drivers

Increasing consumption of tobacco and liquor will drive the growth of the global market.

As per the report from the World Health Organization, it is found that one in three people is overweight. Such statistics are due to the increasing consumption of tobacco and liquor, which is likely to scale up the risk of obesity. Such a landscape further creates critical hypertension, which causes thrombosis-associated problems. Therefore, it is likely to fuel the growth of the global thrombosis drug market exponentially in the forthcoming years. Another crucial factor fueling the growth of the global market is the growing awareness among people regarding the importance of cardiovascular health. However, treating cardiovascular problems with medication is a multifaceted approach, but people are also adopting blood thinner medication as a critical treatment for their problems. Additionally, a number of manufacturers introduced many anticoagulants which address the issues associated with the prevention of blood clots. Such a market landscape will expand the scope of thrombosis drugs. Simultaneously, there is a spike in the number of cases associated with myocardial problems and coronary heart disease, which is also likely to contribute to the growth of the market.

Thrombosis Drug Market: Restraints

Lack of awareness among patients is likely to spur the growth of the global market.

Thrombosis is a result of certain cardiovascular problems due to aging, and nowadays, the geriatric population is growing rapidly. But simultaneously, there is a lack of awareness among people regarding the seriousness of thrombosis, which in turn will also hamper the growth of the global market.

Thrombosis Drug Market: Opportunities

Increasing geriatric population is likely to open new avenues in the global market.

Thrombosis is common in the aging population because it is caused due to cardiovascular problems, which are highly found in aged people. Additionally, the growing disposable income of people is further encouraging them to adopt complete and successful treatment, which is likely to expand the scope of the global market.

Thrombosis Drug Market: Challenges

Side effects of thrombosis drugs are a huge challenge in the global market.

For instance, the common side effect of such drugs is uncontrolled bleeding. Furthermore, anti-clotting medications often cause a stroke. Therefore, such conditions are likely to be a huge challenge in the global market.

North America to hold the largest market share.

In terms of geography, North America held a major share of the global thrombosis drugs market in 2021. High utilization rate of new oral anticoagulant drugs is a key factor that propels the market in North America. Moreover, favorable reimbursement for the treatment of different thrombosis events under Medicare policy also boosts the market in this region. In terms of revenue, the market in Europe and Asia Pacific is projected to expand during the forecast period. Rising prevalence of deep vein thrombosis and increasing awareness about the treatment and usage of drugs to treat different thrombosis events in countries such as Brazil and South Africa are likely to boost the market in Latin America and Middle East & Africa.

Some of the prominent players in the Thrombosis Drugs Market include:

  • Pfizer
  • Aspen Pharmacare Holdings Limited
  • Bayer AG
  • AstraZeneca plc
  • Sanofi
  • Johnson & Johnson
  • Bristol-Myers Squibb Company
  • Baxter International Inc.
  • Boehringer Ingelheim GmbH
  • GlaxoSmithKline plc.

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Thrombosis Drugs market

Drug Class

  • Factor Xa Inhibitor
  • Low Molecular Weight Heparin
  • P2Y12 Platelet Inhibitor
  • Others

Indication

  • Pulmonary Embolism
  • Atrial Fibrillation
  • Deep Vein Thrombosis
  • Others

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Geography

North America

  • U.S.
  • Canada

Europe

  • Germany
  • France
  • United Kingdom
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Southeast Asia
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Rest of Latin America

Middle East & Africa (MEA)

  • GCC
  • North Africa
  • South Africa
  • Rest of Middle East & Africa

Key Benefits for Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global Thrombosis Drugs industry analysis from 2022 to 2030 to identify the prevailing Thrombosis Drugs industry opportunity.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the global Thrombosis Drugs industry segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global Thrombosis Drugs industry trends, key players, market segments, application areas, and market growth strategies.

 

 

Chapter 1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

Chapter 2. Assumptions and Research Methodology

Chapter 3. Executive Summary : Global Thrombosis Drugs Market

Chapter 4. Market Overview
4.1. Introduction
       4.1.1. Drug Class Overview
4.2. Market Dynamics
       4.2.1. Drivers
       4.2.2. Restraints
       4.2.3. Opportunities
4.3. Pipeline Analysis – Thrombosis Drugs Market
4.4. Thrombosis Drugs Sales Analysis
4.5. Thrombosis Drugs Market Value Chain Analysis
4.6. Global Thrombosis Drugs Market Analysis and Forecasts, 2017–2030
       4.6.1. Market Revenue Projection (US$ Mn)
       4.6.2. Market Outlook
4.7. Key Trends

Chapter 5. Global Thrombosis Drugs Market Analysis and Forecasts, by Drug Class
5.1. Key Findings / Developments
5.2. Introduction & Definition
5.3. Market Value Forecast, by Drug Class, 2017–2030
       5.3.1. Factor Xa Inhibitor
       5.3.2. Low Molecular Weight Heparin
       5.3.3. P2Y12 Platelet Inhibitor
       5.3.4. Others
5.4. Market Attractiveness, by Drug Class

Chapter 6. Global Thrombosis Drugs Market Analysis and Forecasts, by Indication
6.1. Key Findings / Developments
6.2. Introduction & Definition
6.3. Market Value Forecast, by Indication, 2017–2030
       6.3.1. Pulmonary Embolism
       6.3.2. Atrial Fibrillation
       6.3.3. Deep Vein Thrombosis
       6.3.4. Others
6.4. Market Attractiveness, by Indication

Chapter 7. Global Thrombosis Drugs Market Analysis and Forecasts, by Distribution Channel
7.1. Key Findings / Developments
7.2. Introduction & Definition
7.3. Market Value Forecast, by Distribution Channel, 2017–2030
       7.3.1. Hospital Pharmacies
       7.3.2. Retail Pharmacies
       7.3.3. Online Pharmacies
7.4. Market Attractiveness, by Distribution Channel

Chapter 8. Global Thrombosis Drugs Market Analysis and Forecasts, by Geography/Region
8.1. Geographical Representation
8.2. Market Value Forecast, by Region
       8.2.1. North America
       8.2.2. Europe
       8.2.3. Asia Pacific
       8.2.4. Latin America
       8.2.5. Middle East & Africa
8.3. Market Attractiveness, by Region

Chapter 9. North America Thrombosis Drugs Analysis and Forecast
9.1. Market Value Forecast, by Country, 2017–2030
       9.1.1. U.S.
       9.1.2. Canada
9.2. Market Value Share Analysis, by Drug Class, 2017–2030
9.3. Market Value Forecast, by Drug Class, 2017–2030
       9.3.1. Factor Xa Inhibitor
       9.3.2. Low Molecular Weight Heparin
       9.3.3. P2Y12 Platelet Inhibitor
       9.3.4. Others
9.4. Market Value Share Analysis, by Indication, 2017–2030
9.5. Market Value Forecast, by Indication, 2017–2030
       9.5.1. Pulmonary Embolism
       9.5.2. Atrial Fibrillation
       9.5.3. Deep Vein Thrombosis
       9.5.4. Others
9.6. Market Value Share Analysis, by Distribution Channel, 2017–2030
9.7. Market Value Forecast, by Distribution Channel, 2017–2030
       9.7.1. Hospital Pharmacies
       9.7.2. Retail Pharmacies
       9.7.3. Online Pharmacies
9.8. Market Attractiveness Analysis
       9.8.1. By Country
       9.8.2. By Drug Class
       9.8.3. By Indication
       9.8.4. By Distribution Channel

Chapter 10. Europe Thrombosis Drugs Market Analysis and Forecast
10.1. Market Value Forecast, by Country , 2017–2030
       10.1.1. Germany
       10.1.2. France
       10.1.3. U.K.
       10.1.4. Spain
       10.1.5. Italy
       10.1.6. Rest of Europe
10.2. Market Value Share Analysis, by Drug Class, 2017–2030
10.3. Market Value and Volume Forecast, by Drug Class, 2017–2030
       10.3.1. Factor Xa Inhibitor
       10.3.2. Low Molecular Weight Heparin
       10.3.3. P2Y12 Platelet Inhibitor
       10.3.4. Others
10.4. Market Value Share Analysis, by Indication, 2017–2030
10.5. Market Value Forecast, by Indication, 2017–2030
       10.5.1. Pulmonary Embolism
       10.5.2. Atrial Fibrillation
       10.5.3. Deep Vein Thrombosis
       10.5.4. Others
10.6. Market Value Share Analysis, by Distribution Channel, 2017–2030
10.7. Market Value Forecast, by Distribution Channel, 2017–2030
       10.7.1. Hospital Pharmacies
       10.7.2. Retail Pharmacies
       10.7.3. Online Pharmacies
10.8. Market Attractiveness Analysis
       10.8.1. By Country
       10.8.2. By Drug Class
       10.8.3. By Indication
       10.8.4. By Distribution Channel

Chapter 11. Asia Pacific Thrombosis Drugs Market Analysis and Forecast
11.1. Market Value Forecast, by Country , 2017–2030
       11.1.1. China
       11.1.2. Japan
       11.1.3. India
       11.1.4. Australia & New Zealand
       11.1.5. Rest of APAC
11.2. Market Value Share Analysis, by Drug Class, 2017–2030
11.3. Market Value and Volume Forecast, by Drug Class, 2017–2030
       11.3.1. Factor Xa Inhibitor
       11.3.2. Low Molecular Weight Heparin
       11.3.3. P2Y12 Platelet Inhibitor
       11.3.4. Others
11.4. Market Value Share Analysis, by Indication, 2017–2030
11.5. Market Value Forecast, by Indication, 2017–2030
       11.5.1. Pulmonary Embolism
       11.5.2. Atrial Fibrillation
       11.5.3. Deep Vein Thrombosis
       11.5.4. Others
11.6. Market Value Share Analysis, by Distribution Channel, 2017–2030
11.7. Market Value Forecast, by Distribution Channel, 2017–2030
       11.7.1. Hospital Pharmacies
       11.7.2. Retail Pharmacies
       11.7.3. Online Pharmacies
11.8. Market Attractiveness Analysis
       11.8.1. By Country
       11.8.2. By Drug Class
       11.8.3. By Indication
       11.8.4. By Distribution Channel

Chapter 12. Latin America Thrombosis Drugs Market Analysis and Forecast
12.1. Market Value Forecast, by Country, 2017–2030
       12.1.1. Brazil
       12.1.2. Mexico
       12.1.3. Rest of LATAM
12.2. Market Value Share Analysis, by Drug Class, 2017–2030
12.3. Market Value and Volume Forecast, by Drug Class, 2017–2030
       12.3.1. Factor Xa Inhibitor
       12.3.2. Low Molecular Weight Heparin
       12.3.3. P2Y12 Platelet Inhibitor
       12.3.4. Others
12.4. Market Value Share Analysis, by Indication, 2017–2030
12.5. Market Value Forecast, by Indication, 2017–2030
       12.5.1. Pulmonary Embolism
       12.5.2. Atrial Fibrillation
       12.5.3. Deep Vein Thrombosis
       12.5.4. Others
12.6. Market Value Share Analysis, by Distribution Channel, 2017–2030
12.7. Market Value Forecast, by Distribution Channel, 2017–2030
       12.7.1. Hospital Pharmacies
       12.7.2. Retail Pharmacies
       12.7.3. Online Pharmacies
12.8. Market Attractiveness Analysis
       12.8.1. By Country
       12.8.2. By Drug Class
       12.8.3. By Indication
       12.8.4. By Distribution Channel

Chapter 13. Middle East & Africa Thrombosis Drugs Market Analysis and Forecast
13.1. Market Value Forecast, by Country, 2017–2030
       13.1.1. GCC Countries
       13.1.2. South Africa
       13.1.3. Israel
       13.1.4. Rest of Middle East & Africa
13.2. Market Value Share Analysis, by Drug Class, 2017–2030
13.3. Market Value and Volume Forecast, by Drug Class, 2017–2030
       13.3.1. Factor Xa Inhibitor
       13.3.2. Low Molecular Weight Heparin
       13.3.3. P2Y12 Platelet Inhibitor
       13.3.4. Others
13.4. Market Value Share Analysis, by Indication, 2017–2030
13.5. Market Value Forecast, by Indication, 2017–2030
       13.5.1. Pulmonary Embolism
       13.5.2. Atrial Fibrillation
       13.5.3. Deep Vein Thrombosis
       13.5.4. Others
13.6. Market Value Share Analysis, by Distribution Channel, 2017–2030
13.7. Market Value Forecast, by Distribution Channel, 2017–2030
       13.7.1. Hospital Pharmacies
       13.7.2. Retail Pharmacies
       13.7.3. Online Pharmacies
13.8. Market Attractiveness Analysis
       13.8.1. By Country
       13.8.2. By Drug Class
       13.8.3. By Indication
       13.8.4. By Distribution Channel

Chapter 14. Competition Landscape
14.1. Competition Matrix
       14.1.1. GlaxoSmithKline plc. F. Hoffmann-La Roche Ltd.
       14.1.2. Baxter International, Inc.
14.2. Company Profiles
       14.2.1. GlaxoSmithKline plc.
                14.2.1.1. Company Details
                14.2.1.2. Company Description
                14.2.1.3. Business Overview
                14.2.1.4. SWOT Analysis
                14.2.1.5. Financial Analysis
                14.2.1.6. Strategic Overview
       14.2.2. Baxter International, Inc.
                14.2.2.1. Company Details
                14.2.2.2. Company Description
                14.2.2.3. Business Overview
                14.2.2.4. SWOT Analysis
                14.2.2.5. Strategic Overview
       14.2.3. Johnson & Johnson
                14.2.3.1. Company Details
                14.2.3.2. Company Description
                14.2.3.3. Business Overview
                14.2.3.4. SWOT Analysis
                14.2.3.5. Strategic Overview
       14.2.4. Bayer AG
                14.2.4.1. Company Details
                14.2.4.2. Company Description
                14.2.4.3. Business Overview
                14.2.4.4. SWOT Analysis
                14.2.4.5. Strategic Overview
       14.2.5. Sanofi
                14.2.5.1. Company Details
                14.2.5.2. Company Description
                14.2.5.3. Business Overview
                14.2.5.4. SWOT Analysis
                14.2.5.5. Financial Analysis
                14.2.5.6. Strategic Overview
       14.2.6. Bristol-Myers Squibb Company
                14.2.6.1. Company Details
                14.2.6.2. Company Description
                14.2.6.3. Business Overview
                14.2.6.4. SWOT Analysis
                14.2.6.5. Financial Analysis
                14.2.6.6. Strategic Overview
       14.2.7. AstraZeneca plc
                14.2.7.1. Company Details
                14.2.7.2. Company Description
                14.2.7.3. Business Overview
                14.2.7.4. SWOT Analysis
                14.2.7.5. Financial Analysis
                14.2.7.6. Strategic Overview
       14.2.8. Pfizer, Inc.
                14.2.8.1. Company Details
                14.2.8.2. Company Description
                14.2.8.3. Business Overview
                14.2.8.4. SWOT Analysis
                14.2.8.5. Financial Analysis
                14.2.8.6. Strategic Overview
       14.2.9. Boehringer Ingelheim GmbH
                14.2.9.1. Company Details
                14.2.9.2. Company Description
                14.2.9.3. Business Overview
                14.2.9.4. SWOT Analysis
                14.2.9.5. Strategic Overview
       14.2.10. Aspen Pharmacare Holdings Limited
                14.2.10.1. Company Details
                14.2.10.2. Company Description
                14.2.10.3. Business Overview
                14.2.10.4. SWOT Analysis
                14.2.10.5. Strategic Overview

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers
Ask To Expert